Literature DB >> 23793761

The role of methylation in urological tumours.

Antoine G van der Heijden1.   

Abstract

Alterations in DNA methylation have been described in human cancer for more than thirty years now. Since the last decade DNA methylation gets more and more important in cancer research. In this review the different alterations of DNA methylation are discussed in testicular germ cell tumours, Wilms'tumours, renal cell carcinomas, urothelial cell carcinomas of the bladder and adenocarcinomas of the prostate. Eventually, the potential use in diagnostics, prognostics and therapy are discussed.

Entities:  

Mesh:

Year:  2013        PMID: 23793761

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  4 in total

1.  Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.

Authors:  Ying-Li Lin; Yan-Ling Wang; Xing-Li Fu; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-11-22

Review 2.  The role of epigenetics in kidney malignancies.

Authors:  Alfredo Harb-De la Rosa; Matthew Acker; Sanjaya Swain; Murugesan Manoharan
Journal:  Cent European J Urol       Date:  2015-04-20

3.  Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Authors:  Ying-Li Lin; Shi-Liang Gui; Hong Guo; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2015-09-25

4.  Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Authors:  Wen-Bin Niu; Shi-Liang Gui; Ying-Li Lin; Xing-Li Fu; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2014-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.